This multi-module curriculum is designed specifically for Medical Case Managers.
This guide is designed to assist health professionals in evaluating medical and dental considerations for treating people with HIV in the era of ART. Oral health professionals play a critical role in...
Comprehensive guidelines, including:
This chart was developed to facilitate continuity of care for people living with HIV who may receive care in both the United States and Mexico. While most HIV medications are now available in both cou...
Colorado AETC of the Mountain West AETC has updated their tri-fold reference guide of current HIV medications. Included are infrequently used medications and formulations.
To order copies call Colorado...
Northeast/Caribbean (NECA) AETC offers online continuing education accredited videos and monographs. Here you can watch NECA AETC lectures, complete self-study modules, and earn continuing education c...
This glossary of HIV/AIDS-related terms includes brief lay-oriented descriptions and illustrations. Materials are in the public domain and may be used freely. The glossary and images are also availabl...
Colorado AETC of the Mountain West AETC has updated its HIV medication chart for providers and patients. This resource features all currently approved antiretroviral drugs and is available as a pad wi...
In response to newly identified, community-based HIV epidemics, the AETC NCRC has pulled together the following AETC Program and U.S. Centers for Disease Control and Prevention resources for public he...
A collection of clinical guides regarding drug interactions of hepatitis C virus (HCV) direct-acting antivirals (DAAs) with other common primary care medications and HIV antiretrovirals.
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment. The AETC National Coordinating Resource Center and its partner,...
Training slides cover HHS recommendations for treatment of transgender people with HIV. Topics incluide HIV-related epidemiology, barriers to care, gender affirmation, including medical gender affirma...
This training slide set covers aging-related concerns for people with HIV, including management of ART. Nearly half of people with HIV in the United States are aged over 50. Topics include epidemiolog...
Three sets of training slides covering what providers treating people with HIV should know about COVID-19. Overall learning objectives include identifying risk factors for and strategies to reduce sev...
This slide set includes an overview of cabotegravir, and provides updates from the phase III PrEP trial and next steps for long-acting PrEP.
Slides from a 1-day course for primary care physicians and mid-level clinicians, which combines the latest research with current treatment guidelines for managing patients with HIV.
Slides from a 2-day training program for primary health and social service providers, which combines recent research with practical guidelines for a comprehensive approach to the care of persons with...
The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention. The 37 lessons and corresponding question bank topics offer...
The HIV Mini-Residency Program is an online, three-day intensive HIV/HCV educational experience. Lectures on a variety of HIV related topics are interspersed with case study and cli...
A basic overview of resistance testing and key aspects of medications used in treatment-experienced patients, review newer medications and their role in HIV treatment. Case-based examples are used to...
The Pacific AETC’s HIV Learning Network (HIVLN) is a free, longitudinal tele-health HIV training and consultation program for HIV clinical care teams and individual clinicians in the Pacific Region. H...
Session 4 of the AETC Program HIV and SARS-CoV-2 Winter Webinar Series (recorded 1/27/21). Presenters discussed the clinical impact of HIV infection and COVID-19, analyzed the latest data on clinical...
Training slides provide an overview of Cabenuva including the latest study findings, adverse effects, resistance, and special dosing considerations.
Training slides review the latest information on HIV injectable therapies in clinical trials, the patients who might be good candidates for this treatment, and potential challenges for providers.
The HIV epidemic is an important public health priority. Transmissions continue to occur despite effective therapies that make HIV preventable and treatable. Approximately one-half of people with HIV...
Presentation slides include information and updates from CROI 2021 regarding:
(Recorded on April 12, 2021)
Paul Edward Sax, MD
Dr. Sax provides a summary of important presentations from the 2021 Conference on Retroviruses and Opportunistic Infections. This...
Training slides cover initial antiretroviral therapy (ART) options based on the most recent HHS Adult/Adolescent Guidelines. Includes selecting the initial ART regimen considering viral load, CD4 coun...
Training slides provide updates on tuberculosis in people with HIV including prevalence, prevention, and treatment.
New England AETC's HIV Resource Library is a compilation of curated resources and education packets on HIV, viral hepatitis, and related public health topics.
Each Library topic page is an organized li...
Training slides covering U.S. HHS treatment recommendations related to starting antiretroviral therapy (ART) in people with HIV infection. Topics include initial screening, regimen selection, and char...
Recommended management strategies for HIV patients experiencing virologic failure (VF) while taking antiretroviral therapy (ART). The potential causes of VF are complex, and require careful assessment...
To help HIV care providers engage patients in care and transmission prevention, the Centers for Disease Control and Prevention (CDC) developed a new and comprehensive Prevention IS Care resource kit f...
Training slides provide a summary of data from the ATLAS and FLAIR studies and outlines a case for patient eligibility for long-acting injectable ART.
Training slides provide a review of the following updated sections to the US Dept. of Health & Human Services (HHS) Adult and Adolescent HIV Treatment Guidelines:
Below is a list of the newest pocket guides created by the MidAtlantic AETC. Descriptions for each resource can be found here:
This quick guide for clinicians discusses the drug interactions between Elbasvir/Grazoprevir (Zepatier™)
This quick guide for clinicians discusses the drug interactions between Glecaprevir/Pibrentasvir (Mavyret™)
This session covers how different HIV medication classes function to suppress viral replication, and reviews current HIV treatment medications and newer HIV treatment regimens.
Dr. Onyema Ogbu...
These presentation slides were from an annual event presented by the Pacific AETC's Arizona regional partner, California Prevention Training Center, and Curry International TB Center for Arizona-based...
Dr. Adrienne E Shapiro discusses highlights from the 2021 IAS Conference.
Training slides review potential ARV drug-drug interactions and identify resources for the evaluation of drug-drug interactions.
Training slides describe the safety and efficacy of the Dapivirine vaginal ring for sustained delivery of ARV drugs.
Training slides define the HIV-ASSIST decision-support tool for ART selection and describe how it's used in different clinical scenarios.
Case-based training slides review new antiretroviral treatment guidelines and medications.
Training slides review the latest updates for the use of PrEP for HIV prevention in the U.S.
Pre-Exposure Prophylaxis (PrEP) is recommended as an HIV prevention option for anyone with risks of acquiring HIV infection through sex or drug use.
PrEP IndicationsDiscuss PrEP...
Training slides provide a summary of HIV prevention updates presented at CROI 2022, including new data on CAB-LA PrEP and other prevention modalities like islatravir, and dapivirine vagina...
Training slides review the following topics from CROI 2022:
Training slides review new/investigational ARTs, emphasize the clinical need for new ART options and paradigms, and review how to select newly approved ARTs for certain clinical situations.
Training slides provide an update on the epidemiology of HIV in the U.S., antiretrovirals, PrEP, the HIV “cure” case, COVID-19 prevention & treatment, and more from CROI 2022.
Training slides provide an overview of the role of cabotegravir/rilpivirine injectables and other novel formulations in development for HIV treatment and prevention, and review shifting treatment para...
Recorded 3/14/22
This seminar focuses on new developments in antiretroviral therapy, including new strategies for the use of existing drugs, recently approved drugs, and new agents on the horizons.
Pres...
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day as the HIV...
After HIV diagnosis, timely entry into HIV medical care and retention in that care are essential to the provision of effective antiretroviral therapy (ART). ART adherence is among the key determinants...
The 69 slides on Occupational Exposure to HIV, HCV, and HBV provide an overview of basic HIV information as well as fulfill the following objectives:
Patient education video discusses basic information about HIV infection, lab values, and the importance of adherence to ART regimen...
This video describes HIV viral replication and where antiretroviral drugs work in the replication process...
The HIV/AIDS Bureau (HAB) of HRSA has developed a series of clinical performance indicators for Ryan White HIV/AIDS Program-funded clinics as part of its quality improvement efforts. The AETC program...
This guideline is a comprehensive compilation of federal recommendations about biomedical, behavioral, and structural interventions that can help reduce the risk of HIV transmission from persons with...
Approximately 7/10 people with HIV in the U.S. are not virally suppressed. This infographic illustrates some of the barriers to achieving viral load suppression, and offers suggestions and resources t...
This report, done by The Black AIDS Institute in collaboration with the CDC, the Latino Commission on AIDS, NASTAD, Johns Hopkins Bloomberg School of Public Health, and Janssen Therapeutics, provides...
AETC HIV and Aging Workgroup
HIV and Aging Toolkit
Trainer slide set on HIV among people aged 50 and older.
Illustrates how improving patient self-management can help to reduce gaps along the HIV care continuum.
Infographic provides recommendations to address gaps in the HIV care continuum related to HIV treatment and prevention for women and their partners.
36 evidence-based recommendations are provided for interventions to optimize the HIV care environment; increase HIV testing and linkage to care, treatment coverage, retention in care, and viral suppre...
Quick guide to oral contraceptives and HIV medications drug interactions.
This infographic identifies the social determinants and risk factors that contribute to new HIV infections among YBMSM (ages 13-24) and offers recommendations for maximizing HIV prevention strategies...
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerula...
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and deat...
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral tenofo...
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with b...
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir du...
We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART ver...
The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples engage...
This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who participa...
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the vulnerability of dolutegr...
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG) plus 2...
The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-tablet re...
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the DOR...
In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as prescribed and achieve and...
The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing darunavir 800 mg/cobi...
The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC) has been shown in four Phase III trials to be effective as initial therapy.Also as a switch regimen in patients with stably suppressed HIV RNA and no resistance to BIC, TAF, or FTC. In these stu...
Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of treatment failure...
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain inter...
The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with susceptible HIV, an...
PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).
PARTNER1 evaluated HIV transmission risk in a European multicenter...
Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.
The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43 pregnant women. For women taking 25 mg of TAF da...
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is intend...
In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher propo...
In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope glycoprote...
A long-acting formulation of the investigational integrase inhibitor cabotegravir (CAB) is being studied as a single agent for HIV prevention. (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir + Ril...
TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) n = 369) or continued their baseline ART (n = 372). Previously published data showed no significant differ...
The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (the...
Lenacapavir (LEN) is a novel investigational long-acting injectable ARV that is administered every 6 months by subcutaneous (SC) injection. It is an HIV-1 capsid inhibitor that acts at several points in the HIV life cycle. As a novel class, has full activity against viruses with resistance to the NR...
We recognize the work of our AETC colleagues who dedicate additional time and resources to research beyond the scope of the AETC Program. The following is a compilation of HIV-related peer-reviewed studies produced by AETC-affiliated researchers and faculty, published in 2021.
If you're aware of othe...
...
...
...
...
